Key result
Olmesartan significantly reduced microvessel density and serum levels of VEGF and IGF-I in a dose-dependent manner, potentiating the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma.
Why the study?
Does olmesartan alone or in combination with sorafenib reduce tumor angiogenesis in mice bearing Ehrlich's ascites carcinoma?
Does olmesartan alone or in combination with sorafenib reduce tumor angiogenesis in mice bearing Ehrlich's ascites carcinoma?
Answers are grounded in this paper and cite their sources.
Olmesartan reduces angiogenesis markers and potentiates the anti-angiogenic effect of sorafenib in a mouse model of Ehrlich's ascites carcinoma, mediated by the angiotensin (1-7) receptor.
Local renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further evaluated. The present study was carried out to investigate the anti-angiogenic effect of olmesartan alone or in combination with sorafenib, an angiotensin (1-7) agonist or an angiotensin (1-7) antagonist in Ehrlich's ascites carcinoma-bearing mice. The tumor was induced by intradermal injection of Ehrlich's ascites carcinoma cells into mice. Tumor discs were used to evaluate the microvessel density; the serum levels of vascular endothelial growth factor (VEGF) and serum insulin-like growth factor I (IGF-I); and their intratumoral receptors, VEGF receptor-2 and IGF-I receptor, respectively. All parameters were determined following the treatment course, which lasted for 21 days post-inoculation. Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors. In addition, the combination of olmesartan (30 mg/kg) with an angiotensin (1-7) agonist reduced the microvessel density, IGF-I serum levels and the levels of its intratumoral receptor. In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin (1-7) receptor. These results suggest that olmesartan is a promising adjuvant to sorafenib in the treatment of cancer.
No takes yet. Share an insight, caveat, or question.
Abd‐Alhaseeb et al. (2014) studied Ehrlich's ascites carcinoma (n=90). Olmesartan and Sorafenib vs. DMSO (EAC-control) was evaluated on Microvessel density, serum levels of VEGF and IGF-I, and intratumoral receptors (p=<0.05). Olmesartan significantly reduced microvessel density and serum levels of VEGF and IGF-I in a dose-dependent manner, potentiating the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: